Meeting
2022 ASCO Annual Meeting
Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible.
Authors
Daniel P. Petrylak
Yale Cancer Center, New Haven, CT
Daniel P. Petrylak , Thomas W. Flaig , Nataliya Mar , Theodore Stewart Gourdin , Sandy Srinivas , Jonathan E. Rosenberg , Maria Guseva , Yao Yu , Sujata Narayanan , Christopher J. Hoimes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Local-Regional Disease
Clinical Trial Registration Number
NCT03288545
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4582)
DOI
10.1200/JCO.2022.40.16_suppl.4582
Abstract #
4582
Poster Bd #
73
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H.
First Author: Thomas W. Flaig
Poster
2022 ASCO Genitourinary Cancers Symposium
Study EV-103 cohort L: Evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (trial in progress).
First Author: Christopher J. Hoimes
Poster
2024 ASCO Genitourinary Cancers Symposium
Enfortumab vedotin (EV) in cisplatin-eligible and ineligible patients with advanced urothelial cancer (aUC): A single-center experience.
First Author: Evangelia Vlachou